Pfizer (PFE) Misses Q4 EPS by 2c, Offers FY20 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE) Following 4Q
January 29, 2020 7:04 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $53.00 price target on Pfizer (NYSE: PFE) following the company's 4Q earnings report. PFE reported 4Q19 adjusted diluted EPS of $0.55, $0.03 lower than consensus.
PFE presented its 2020 sales and EPS guidance of $48.5-50.5B and... More
Pfizer (PFE) CEO, Never Says Never, But We Don't Want Big M&A - Bloomberg, Citing Call
January 28, 2020 10:59 AM ESTPfizer (NYSE: PFE) CEO, Never Says Never, But We Don't Want Big M&A - Bloomberg, Citing Call
